Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 19, Issue 1, Pages 78-86
Publisher
Wiley
Online
2016-09-08
DOI
10.1111/dom.12786
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vertebral Fractures: Clinical Importance and Management
- (2016) D.L. Kendler et al. AMERICAN JOURNAL OF MEDICINE
- Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study
- (2016) Sumit R. Majumdar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Type 2 diabetes and the skeleton: new insights into sweet bones
- (2016) Vikram V Shanbhogue et al. Lancet Diabetes & Endocrinology
- Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
- (2015) Ofri Mosenzon et al. DIABETES CARE
- The Impact of Diabetes and Diabetes Medications on Bone Health
- (2015) Matthew P. Gilbert et al. ENDOCRINE REVIEWS
- Trabecular Bone Score as an Indicator for Skeletal Deterioration in Diabetes
- (2015) Jung Hee Kim et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review
- (2015) A. Palermo et al. OSTEOPOROSIS INTERNATIONAL
- Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs
- (2015) Johanna H. M. Driessen et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
- (2014) Johanna H.M. Driessen et al. BONE
- Increased Risk of Fracture and Postfracture Adverse Events in Patients With Diabetes: Two Nationwide Population-Based Retrospective Cohort Studies
- (2014) Chien-Chang Liao et al. DIABETES CARE
- Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
- (2013) Jennifer B. Green et al. AMERICAN HEART JOURNAL
- TBS (Trabecular Bone Score) and Diabetes-Related Fracture Risk
- (2013) William D. Leslie et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials (胰高血糖素样肽-1受体激动剂的使用与骨折的关系：一项对随机临床试验的meta分析)
- (2013) Guillaume Mabilleau et al. Journal of Diabetes
- Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial
- (2012) A. V. Schwartz et al. DIABETES CARE
- Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes
- (2012) S. S. Johnston et al. DIABETES OBESITY & METABOLISM
- Type 2 diabetes and bone
- (2012) William D Leslie et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials
- (2011) M. Monami et al. DIABETES CARE
- FRAX underestimates fracture risk in patients with diabetes
- (2011) Lora M Giangregorio et al. JOURNAL OF BONE AND MINERAL RESEARCH
- FRAX® and its applications to clinical practice
- (2009) John A. Kanis et al. BONE
- Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)
- (2008) S. E. Kahn et al. DIABETES CARE
- Fracture Risk in Type 2 Diabetes: Update of a Population-Based Study
- (2008) L Joseph Melton et al. JOURNAL OF BONE AND MINERAL RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started